Yes, Kevzara Can Be Used with Methotrexate
Kevzara (sarilumab) is approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to one or more tumor necrosis factor (TNF) antagonists. Clinical studies and prescribing information support its use alongside methotrexate (MTX), a common disease-modifying antirheumatic drug (DMARD). In the pivotal MOBILITY trial, patients on stable MTX (typically 7.5-20 mg/week) received Kevzara 200 mg or 150 mg subcutaneously every two weeks, showing significant improvements in signs and symptoms of RA compared to placebo.[1][2]
How It's Typically Combined in Practice
Rheumatologists often prescribe Kevzara with MTX as first-line combination therapy for RA patients with inadequate response to MTX alone. The recommended starting dose is 200 mg every two weeks, reduced to 150 mg if needed for lab abnormalities or tolerability. No dose adjustments for MTX are required when combined, but monitor liver enzymes, blood counts, and lipids closely due to increased hepatotoxicity risk.[1][3]
What the Trials Showed for Combination Efficacy
Phase 3 trials like MOBILITY (MTX-refractory patients) demonstrated ACR20 response rates of 61% (200 mg) and 55% (150 mg) with Kevzara plus MTX, versus 36% for placebo plus MTX. Similar benefits appeared in TARGET (TNF-inadequate responders), confirming additive effects without MTX withdrawal.[2][4]
Potential Risks and Monitoring Needs
Combining raises infection risk (e.g., upper respiratory, herpes zoster) and lab issues like neutropenia or elevated ALT/AST. Use lowest effective MTX dose; discontinue if severe issues arise. Avoid in active infections or with live vaccines.[1][3] Patient reports note manageable GI upset or fatigue, but regular bloodwork is standard.
When to Avoid or Adjust the Combo
Skip if MTX intolerance, liver disease, or cytopenias exist. For elderly patients or those with renal impairment, lower MTX doses may be needed independently. No Kevzara-specific interactions beyond general immunosuppressant overlap.[1]
Alternatives if Methotrexate Isn't Suitable
Switch to Kevzara monotherapy (less effective per trials) or pair with other DMARDs like leflunomide. Competitors like Olumiant (baricitinib) or Rinvoq (upadacitinib) also combine with MTX.[2][5]
[1]: Kevzara Prescribing Information (Sanofi/Regeneron)
[2]: FDA Approval Summary for Kevzara
[3]: Drugs.com Drug Interactions Checker: Sarilumab + Methotrexate
[4]: New England Journal of Medicine: Sarilumab in RA (MOBILITY Trial)
[5]: Arthritis Foundation RA Treatment Guidelines